Table 1.
Patient characteristics by reconstruction type.
| Characteristic | IBR (n = 112) | ABR (n = 224) | P value |
|---|---|---|---|
| Age (mean ± SD) | 56.4 ± 11.3 | 55.0 ± 8.9 | 0.256 |
| Body Mass Index (mean ± SD) | 24.2 ± 3.9 | 26.3 ± 4.2 | <0.001 |
| Breast cup size preoperatively (n, %) | <0.001 | ||
| AA | 2 (1.8) | 0 (0) | |
| A | 12 (10.7) | 9 (4) | |
| B | 49 (43.8) | 61 (27.2) | |
| C | 16 (14.3) | 64 (28.6) | |
| D | 20 (17.9) | 55 (24.6) | |
| E | 11 (9.8) | 24 (10.7) | |
| >E | 2 (1.8) | 10 (4.5) | |
| Smoking (n, %) | <0.001 | ||
| Yes | 21 (18.8) | 10 (4.5) | |
| No | 91 (81.3) | 214 (95.5) | |
| Allergies (n, %) | 0.146 | ||
| Yes | 28 (25.0) | 73 (32.6) | |
| No | 84 (75.0) | 150 (67.0) | |
| Chronic disease, self-reported (n, %) | 0.569 | ||
| Yes | 24 (21.4) | 54 (24.1) | |
| No | 88 (78.6) | 169 (75.4) | |
| Relationship (n, %) | 0.775 | ||
| Yes | 88 (78.6) | 179 (79.9) | |
| No | 24 (21.4) | 45 (20.1) | |
| Children (n, %) | 0.190 | ||
| Yes | 95 (84.8) | 201 (89.7) | |
| No | 17 (15.2) | 23 (10.3) | |
| Educational level | 0.001 | ||
| 1 – No education | 0 (0) | 0 (0) | |
| 2 – Elementary education | 5 (4.5) | 1 (0.4) | |
| 3 – Secondary education | 24 (21.4) | 25 (11.2) | |
| 4 – Middle-level vocational education/ | 43 (38.4) | 95 (42.4) | |
| 5 – Higher-level vocational education/college/university | 36 (32.1) | 77 (34.4) | |
| 6 – Academic/doctoral degree | 3 (2.7) | 25 (11.2) | |
| Reconstruction timing (n, %) | <0.001 | ||
| Primary | 88 (78.6) | 121 (54.0) | |
| Secondary | 24 (21.4) | 103 (46.0) | |
| Laterality (n, %) | 0.938 | ||
| Unilateral BR | 62 (55.4) | 125 (55.8) | |
| Bilateral BR | 50 (44.6) | 99 (44.2) | |
| Complications (n, %) | 0.173 | ||
| Yes | 32 (28.6) | 82 (36.6) | |
| No | 78 (69.6) | 142 (63.4) | |
| Follow-up duration after reconstruction in months (mean ± SD) | 51.5 ± 14.3 | 44.3 ± 14.6 | <0.001 |
| Mastectomy indication | |||
| Invasive carcinoma | 82 (73.2) | 170 (75.9) | 0.790 |
| In situ carcinoma/non-cancerous pathology | 17 (15.2) | 28 (12.5) | |
| Bilateral prophylactic mastectomy | 13 (11.6) | 26 (11.6) | |
| Tumor stage at diagnosisa | |||
| T | 0.822 | ||
| 1 | 43 (38.4) | 82 (36.6) | |
| 2 | 28 (25.0) | 63 (28.1) | |
| 3 | 5 (4.5) | 8 (3.6) | |
| N | <0.001 | ||
| 0 | 63 (56.3) | 92 (41.1) | |
| 1 | 12 (10.7) | 51 (22.8) | |
| 2 | 1 (0.9) | 8 (3.6) | |
| 3 | 0 (0) | 4 (1.8) | |
| M | 1.000 | ||
| 0 | 81 (100) | 168 (100) | |
| Bloom & Richardson [1] | 0.876 | ||
| Grade 1 | 15 (18.3) | 26 (15.3) | |
| Grade 2 | 35 (42.7) | 71 (41.8) | |
| Grade 3 | 17 (20.7) | 32 (18.8) | |
| Chemotherapy (%) | 0.151 | ||
| Yes | 54 (48.2) | 126 (56.3) | |
| No | 58 (51.8) | 97 (43.3) | |
| Radiotherapy (%) | 0.001 | ||
| Yes | 20 (17.9) | 81 (36.2) | |
| No | 92 (82.1) | 142 (63.4) | |
| Hormone therapy (n, %) | 0.040 | ||
| Yes | 40 (35.7) | 106 (47.3) | |
| No | 72 (64.3) | 117 (52.2) | |
| Immunotherapy (n, %) | 0.643 | ||
| Yes | 32 (14.3) | ||
| No | 191 (85.3) | ||
a
Only invasive tumors included.